Skip to main content
Top
Published in: Rheumatology International 6/2009

01-04-2009 | Case Report

Successful treatment of SAPHO syndrome with an oral bisphosphonate

Authors: Jiro Ichikawa, Eiichi Sato, Hirotaka Haro, Takashi Ando, Singo Maekawa, Yoshiki Hamada

Published in: Rheumatology International | Issue 6/2009

Login to get access

Abstract

The etiology of the synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome remains unclear and treatment with various drugs for SAPHO syndrome often fails. But recently the effectiveness of intravenous bisphosphonates (BPs) for SAPHO syndrome has been reported in many cases and the use of intravenous BPs as first choice drug has been thought to be effective. On the other hand, serious side effects of intravenous BPs were reported in some cases. This is the first reported case of successful treatment of SAPHO syndrome with an oral BPs, the use of which is safer and more practical than intravenous BPs.
Literature
5.
7.
go back to reference Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744. doi:10.1002/cncr.11701 PubMedCrossRef Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744. doi:10.​1002/​cncr.​11701 PubMedCrossRef
8.
11.
go back to reference Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M et al (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388. doi:10.1007/s00774-005-0616-5 PubMedCrossRef Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M et al (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388. doi:10.​1007/​s00774-005-0616-5 PubMedCrossRef
12.
go back to reference Solau-Gervais E, Soubrier M, Gerot I, Grange L, Puechal X, Sordet C et al (2006) The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford) 45:339–342. doi:10.1093/rheumatology/kei160 CrossRef Solau-Gervais E, Soubrier M, Gerot I, Grange L, Puechal X, Sordet C et al (2006) The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford) 45:339–342. doi:10.​1093/​rheumatology/​kei160 CrossRef
Metadata
Title
Successful treatment of SAPHO syndrome with an oral bisphosphonate
Authors
Jiro Ichikawa
Eiichi Sato
Hirotaka Haro
Takashi Ando
Singo Maekawa
Yoshiki Hamada
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0760-z

Other articles of this Issue 6/2009

Rheumatology International 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.